Summit Financial Wealth Advisors LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 17.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,637 shares of the company’s stock after selling 572 shares during the period. Summit Financial Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $343,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Harding Loevner LP bought a new stake in Johnson & Johnson during the second quarter valued at approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. IHT Wealth Management LLC grew its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $177,000. 65.53% of the stock is owned by institutional investors.
A number of equities analysts have weighed in on JNJ shares. Cowen reiterated an “outperform” rating and issued a $155.00 price target (up from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Barclays upped their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research report on Friday, January 12th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $146.16.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. Johnson & Johnson’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.58 earnings per share. equities analysts expect that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s payout ratio is 861.54%.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Stake Decreased by Summit Financial Wealth Advisors LLC” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/02/15/summit-financial-wealth-advisors-llc-has-343000-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.